Form 4: VolitionRX Director Innes Receives Stock Units in Lieu of Cash Compensation

Director Guy Archibald Innes of VolitionRX Ltd. reports the acquisition of 18,342 restricted stock units (RSUs) in lieu of cash compensation, along with holdings through various trusts.

Summary

• Guy Archibald Innes, a director of VolitionRX Ltd., filed a Form 4 detailing changes in beneficial ownership.
• On September 1, 2024, Innes received 18,342 restricted stock units (RSUs) under the company's 2015 Stock Incentive Plan as a substitute for cash compensation.
• These RSUs vest in installments on September 1, 2024, October 1, 2024, and November 1, 2024, with final vesting on June 1, 2025, contingent upon continued service.
• Upon vesting, Innes will receive common stock equivalent to the number of vested RSUs.
• Innes also reports indirect ownership of VolitionRX common stock through The Innes Family Bare Trust 2023 (1,400,000 shares), The Dill Faulkes Educational Trust Limited (356,000 shares), and holdings by his children (154,503 or 154,504 shares each).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock unit grants, which is neither particularly positive nor negative.

Positives

• The acceptance of RSUs in lieu of cash compensation may indicate a belief in the company's future prospects by the director.
• The vesting schedule incentivizes continued service by the director.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The acceptance of stock in lieu of cash is not uncommon.

Stakeholder Impact

• The grant of RSUs aligns the director's interests with those of shareholders, as the value of the RSUs is tied to the company's stock performance.

Key Dates